Credit Agreement and GuarantyCredit Agreement • December 16th, 2021 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
Credit Agreement And Guaranty, dated as of December 15, 2021 (this “Agreement”), among Trinity Biotech, Inc., a Delaware corporation (“U.S. Holdings”), Fitzgerald Industries International, Inc., a Delaware corporation (“U.S. Fitzgerald”) Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), Biopool US Inc., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), Primus Corporation, a Missouri corporation (“U.S. Primus”), MarDx Diagnostics, Inc., a California corporation (“U.S. MarDx”), IMMCO Diagnostics, Inc., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Biopool, U.S. Primus and U.S. MarDx, each a “Borrower” and collectively, the “Borrowers”), certain Guarantors from time to time parties hereto, the lenders from time to time party hereto (each, as a “Lender” and collectively, the “Lenders”), and Perceptive Credit Holdings III, LP, a Delaware limited partnership (“Pe
EXCHANGE AGREEMENTExchange Agreement • December 16th, 2021 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS EXCHANGE AGREEMENT (this “Agreement”) is made as of December , 2021 by and between Trinity Biotech Investment Limited, as Issuer (the “Company”), Trinity Biotech Plc, as Guarantor (the “Parent”), and [ ], (the “Holder”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them set forth in the Indenture, dated as of April 9, 2015 (the “Indenture”), by and among the Company, the Parent and Wilmington Trust, National Association, as Trustee (the “Trustee”).
